Research information only. PrecisePep is an educational library. It is not medical advice and is not intended to assist, encourage or enable self-administration. The compounds documented here are research chemicals — most are not approved for human use. Read the full disclaimer.
PrecisePep/Peptide Library/Desmopressin
Endocrine & Reproductive Axis
DDAVP® · Nocdurna® · Noctiva® · Minirin® · 1-desamino-8-D-arginine vasopressin
Vasopressin with the blood-pressure effect engineered out and the water effect left in — two small changes to a nine-residue hormone that turned a vasoconstrictor into the treatment for diabetes insipidus.
Vasopressin does two jobs through two different receptors, and for most clinical purposes you want one of them and not the other. V1 receptors on vascular smooth muscle produce vasoconstriction. V2 receptors in the renal collecting duct produce water reabsorption. Native vasopressin hits both, which makes it useful in shock and unsuitable for anything requiring chronic use.
Desmopressin is what happens when you remove the amino group at position one and swap the L-arginine at position eight for its D-isomer. The result is strongly V2-selective, resistant to degradation, and long enough acting to be dosed once or twice a day. It concentrates urine without raising blood pressure.[1]
That gave it a set of indications that look unrelated until you trace them back to water handling: central diabetes insipidus, where the pituitary no longer makes vasopressin; primary nocturnal enuresis in children; nocturia due to nocturnal polyuria in adults; and — through a mechanism that has nothing to do with the kidney — mild haemophilia A and von Willebrand disease type 1, where V2 stimulation of endothelial Weibel-Palade bodies releases stored factor VIII and von Willebrand factor into the circulation.[2]
The risk profile follows directly from the mechanism. A drug that makes the kidney retain water will cause dilutional hyponatraemia in anyone who keeps drinking normally. That is the boxed warning, and severe hyponatraemia causes seizures, coma and death.[3]
Desmopressin is a prescription medicine and this page publishes no unsupervised dosing for it. It appears because the conditions index names diabetes insipidus and enuresis among conditions with approved peptide treatments.
The one thing to understand about it: the drug does not cause hyponatraemia on its own — the combination of the drug and normal fluid intake does. Fluid restriction around dosing is part of the treatment, not advice attached to it. This is the mechanism by which desmopressin kills people, and it is entirely preventable.
V2 receptor agonism in the collecting duct. Binding raises intracellular cyclic AMP, which drives aquaporin-2 water channels into the apical membrane of the collecting duct cell. Water moves out of the tubule down the medullary osmotic gradient. Urine volume falls and urine osmolality rises.
V1 avoidance. The structural modifications reduce V1 affinity substantially. Native vasopressin's pressor effect is largely absent, which is what permits repeated dosing.
Factor VIII and von Willebrand factor release. V2 receptors on vascular endothelium trigger exocytosis of Weibel-Palade bodies, releasing stored von Willebrand factor and, with it, factor VIII. Plasma levels rise several-fold within roughly 30 to 60 minutes. This works only where stores exist — it is useful in mild haemophilia A and von Willebrand disease type 1, and useless in severe deficiency where there is nothing to release. Repeated dosing depletes the stores, producing tachyphylaxis.[2]
Why hyponatraemia follows. Water retention without solute retention dilutes serum sodium. If intake continues unchanged while excretion is pharmacologically blocked, sodium falls. Thiazides, SSRIs, tricyclics, carbamazepine, NSAIDs, opioids and glucocorticoids all compound this, and older adults are considerably more susceptible.[3]
Effects that have been reported. A study-tier entry means a result was published — not that the effect is established, reproducible, or transferable from a rodent to a person.
Highest confidenceReported in peer-reviewed literature, registered clinical trials, or regulatory filings. Note the model: much peptide literature is in vitro or rodent work, not human trial data.
Directly replaces the missing hormone, restoring urine concentrating ability. Controls polyuria and polydipsia in a condition that is otherwise defined by them. The clearest form of replacement pharmacology in this library.
Reduces night-time urine production, with randomised evidence supporting reduction in wet nights. Enuresis alarms have better long-term cure rates; desmopressin acts faster and is often used situationally.
Approved low-dose sublingual and nasal formulations, with sex-specific dosing reflecting a higher hyponatraemia risk in women at equivalent doses. The dose is deliberately far below the diabetes insipidus range.
Raises factor VIII and von Willebrand factor several-fold, sufficient to cover dental procedures, minor surgery and bleeding episodes without factor concentrate. A trial dose is given first to confirm the individual responds.
Oral tablets, sublingual lyophilisate, nasal spray, and subcutaneous or intravenous injection — with substantially different potency between routes, which is the source of most dosing errors involving this drug.
Unproven — inference onlyExtrapolated from a known mechanism, receptor profile, or adjacent compound class. Biologically plausible but not directly demonstrated for this compound in this context.
Used off-label to improve haemostasis in uraemic platelet dysfunction and in some antiplatelet-associated bleeding. Reasonable mechanistically, with an evidence base that is largely observational.
Does not work — the defect is receptor or aquaporin-level insensitivity in the kidney, not a shortage of hormone. Distinguishing central from nephrogenic disease is the whole diagnostic question.
Plasma volume expansion can dilute urinary markers, which is precisely why desmopressin is explicitly named on the WADA Prohibited List as a masking agent.
Uncontrolled reportsAggregated from research-community logs, forums, vendor literature and self-reported experience. Uncontrolled, unverified, subject to placebo, polypharmacy and product-purity confounds. Lowest evidentiary weight.
Patient reporting describes the return of ordinary sleep and the end of constant thirst, which is what replacing a missing hormone should look like.
A widely described pattern in enuresis, and a reasonable one given the drug acts on the night it is taken.
Nasal, sublingual, oral and injectable strengths are not interchangeable and differ by more than an order of magnitude in places. Errors when switching routes are a documented and recurring problem.
Where it appears outside prescription channels it is generally in a doping or bodybuilding context as a masking or "fullness" agent. Both uses risk severe hyponatraemia and one is explicitly banned in sport.
Adverse effects, contraindications and unknowns. The grey-market tier is where under-reporting is worst: uncontrolled use produces no systematic safety surveillance at all, so absence of a reported harm is not evidence of safety.
Highest confidenceReported in peer-reviewed literature, registered clinical trials, or regulatory filings. Note the model: much peptide literature is in vitro or rodent work, not human trial data.
Severe hyponatraemia can be life-threatening, causing seizures, coma, respiratory arrest and death. Serum sodium should be measured within seven days and at approximately one month after starting, then periodically, with more frequent monitoring in people aged 65 and over.
The label directs that fluid intake be limited to a minimum from one hour before until eight hours after administration. Treatment without concurrent fluid reduction leads to retention and hyponatraemia.
Excessive fluid intake, illnesses causing fluid or electrolyte imbalance, loop diuretic use, systemic or inhaled glucocorticoid use, moderate to severe renal impairment, and known hyponatraemia are contraindications on the relevant labels.
Tricyclic antidepressants, SSRIs, chlorpromazine, opioid analgesics, thiazide diuretics, carbamazepine, lamotrigine, sulfonylureas — chlorpropamide in particular — and NSAIDs all increase hyponatraemia risk.
The common adverse events, and also early symptoms of hyponatraemia — which is why they are not simply reassured away.
Rhinitis, epistaxis and nasal discomfort with the intranasal routes; absorption also varies with nasal congestion, which makes the route less predictable.
Unproven — inference onlyExtrapolated from a known mechanism, receptor profile, or adjacent compound class. Biologically plausible but not directly demonstrated for this compound in this context.
Repeated doses deplete endothelial stores, so the factor VIII response diminishes with each dose over a short interval. This limits it to short haemostatic cover rather than ongoing therapy.
Age-related decline in water handling, higher comorbidity and greater polypharmacy converge. The nocturia labels reflect this in their monitoring requirements.
Rare reports exist, plausible given the mechanism raises procoagulant factors. Caution in patients with cardiovascular disease.
Uncontrolled reportsAggregated from research-community logs, forums, vendor literature and self-reported experience. Uncontrolled, unverified, subject to placebo, polypharmacy and product-purity confounds. Lowest evidentiary weight.
Commonly reported, and the symptom most likely to signal falling sodium.
Repeatedly described, and the single most important compliance issue with this drug.
Consistent with the pharmacokinetics of the intranasal route.
Figures below are documented, not recommended. Study ranges come from published protocols in the stated model; grey-market ranges are what the research community reports using and carry no safety validation of any kind.
Highest confidenceReported in peer-reviewed literature, registered clinical trials, or regulatory filings. Note the model: much peptide literature is in vitro or rodent work, not human trial data.
Central diabetes insipidus, enuresis, nocturia and haemostatic use each have distinct dose ranges, and oral, sublingual, intranasal and injectable strengths are not interchangeable. Doses are individualised and titrated. This site publishes no figures because a transcription error between routes is exactly how this drug causes harm.
The sublingual nocturia product uses different doses in men and women, reflecting a higher observed hyponatraemia risk in women at equivalent exposure — an unusual and deliberate feature of the label.
Individual response varies. A test dose with measurement of factor VIII or von Willebrand factor before relying on it for a procedure is standard practice.
Within seven days of starting, at approximately one month, and periodically thereafter — more frequently in people over 65 or at elevated risk.
| Aspect | Detail | Note |
|---|---|---|
| Routes | Oral, sublingual, intranasal, SC, IV | Not interchangeable |
| Fluid restriction | 1 h before to 8 h after dosing | Part of the treatment |
| Sodium check | Day 7, ~1 month, then periodic | More often if aged 65+ |
| Nocturia dosing | Lowest range; sex-specific | Higher risk in women at equal dose |
| Haemostatic use | Trial dose first | Tachyphylaxis on repeat dosing |
| Does not treat | Nephrogenic diabetes insipidus | Wrong lesion — kidney, not pituitary |
| Sport | Prohibited as a masking agent | Named on the WADA list |
Unproven — inference onlyExtrapolated from a known mechanism, receptor profile, or adjacent compound class. Biologically plausible but not directly demonstrated for this compound in this context.
Hyponatraemia risk is dose-related, which makes conservative titration the default clinical approach across every indication.
Uncontrolled reportsAggregated from research-community logs, forums, vendor literature and self-reported experience. Uncontrolled, unverified, subject to placebo, polypharmacy and product-purity confounds. Lowest evidentiary weight.
A drug whose principal risk is detected by a blood test and whose safe use depends on fluid restriction is not one this site provides unsupervised figures for.
Combination effects. Almost no peptide combination has been studied as a combination in humans; stack logic is overwhelmingly mechanistic inference and community practice. Each linked compound has its own page.
Highest confidenceReported in peer-reviewed literature, registered clinical trials, or regulatory filings. Note the model: much peptide literature is in vitro or rodent work, not human trial data.
Antifibrinolytic cover alongside desmopressin is standard for dental and mucosal procedures in mild bleeding disorders.
Unproven — inference onlyExtrapolated from a known mechanism, receptor profile, or adjacent compound class. Biologically plausible but not directly demonstrated for this compound in this context.
Thiazides, SSRIs, tricyclics, carbamazepine, NSAIDs and opioids each independently promote water retention or SIADH. Combined with desmopressin the risk is not additive so much as compounding.
Contraindications rather than cautions. Nocturia is a quality-of-life indication, so the tolerable risk is set much lower than it would be for a condition that threatened something.
Terlipressin is V1-preferring and used for splanchnic vasoconstriction in hepatorenal syndrome and variceal bleeding. Same hormone family, opposite receptor emphasis, entirely different indications.
Uncontrolled reportsAggregated from research-community logs, forums, vendor literature and self-reported experience. Uncontrolled, unverified, subject to placebo, polypharmacy and product-purity confounds. Lowest evidentiary weight.
Patients with diabetes insipidus commonly describe adjusting around vomiting, diarrhoea or fever, when fluid and electrolyte balance shifts. This is a conversation for a clinician, not a rule of thumb.
Whole schedules — dosing, titration, cycle length, and off-time — as documented in trials, as proposed from mechanism, and as circulated in the research community. Reproduced for study and comparison only.
Highest confidenceReported in peer-reviewed literature, registered clinical trials, or regulatory filings. Note the model: much peptide literature is in vitro or rodent work, not human trial data.
Central and nephrogenic diabetes insipidus are distinguished by response to water deprivation followed by desmopressin — copeptin measurement has increasingly replaced the classical test. Desmopressin is diagnostic before it is therapeutic.
Serum sodium at day seven, one month and periodically, with treatment stopped if sodium falls below the labelled threshold.
Response confirmed biochemically before a procedure is planned around it.
Unproven — inference onlyExtrapolated from a known mechanism, receptor profile, or adjacent compound class. Biologically plausible but not directly demonstrated for this compound in this context.
Given how central fluid restriction is to safety, providing it in writing rather than verbally is the reasonable default.
Uncontrolled reportsAggregated from research-community logs, forums, vendor literature and self-reported experience. Uncontrolled, unverified, subject to placebo, polypharmacy and product-purity confounds. Lowest evidentiary weight.
Patients with diabetes insipidus commonly describe having a plan agreed in advance for illness. Sensible, and something to establish with a clinician rather than improvise.
The approved indications are covered above. This section covers the off-label uses, the one rule that determines whether this drug is safe, and the reason it is explicitly banned in sport.
The nocturia formulations carry a boxed warning for hyponatraemia. Severe hyponatraemia causes seizures, coma, respiratory arrest and death. The drug does not cause it alone — the combination of the drug and normal fluid intake does, which is why fluid restriction around dosing is part of the treatment rather than advice attached to it.
Pathophysiology
Desmopressin makes the kidney retain water without retaining solute. If intake continues unchanged while excretion is pharmacologically blocked, serum sodium falls.
Mechanistic rationale
Fluid intake should be limited from one hour before until eight hours after dosing, and serum sodium checked within seven days, at about one month, and periodically after. Risk rises sharply in people over 65 and with common drugs — thiazides, SSRIs, tricyclics, carbamazepine, NSAIDs, opioids. Early hyponatraemia symptoms are headache, nausea and abdominal pain, which is also the ordinary side effect profile, so the two are indistinguishable without a blood test.
Community reports
Difficulty complying with fluid restriction is the most consistently described problem, and it is the mechanism by which this drug harms people.
Components carrying the argument: V2 receptor — water retention
Pathophysiology
V2 receptors on vascular endothelium trigger release of stored von Willebrand factor and factor VIII from Weibel-Palade bodies.
Mechanistic rationale
This has nothing to do with the kidney. It raises factor levels several-fold within about an hour, which covers dental work and minor surgery in mild haemophilia A and von Willebrand disease type 1. It works only where stores exist — useless in severe deficiency — and repeated dosing depletes them, producing tachyphylaxis. Also used off-label in uraemic platelet dysfunction.
Community reports
A trial dose with factor measurement before relying on it for a procedure is standard, because response varies between individuals.
Components carrying the argument: Endothelial Weibel-Palade body exocytosis
Pathophysiology
Plasma volume expansion dilutes urinary and blood markers used in anti-doping analysis.
Mechanistic rationale
Desmopressin is named on the WADA Prohibited List as a masking agent, prohibited at all times and in all sports. That is not a borderline classification arrived at by category — it is named. Where this compound appears outside prescription channels it is generally in a doping or physique context, and both uses risk severe hyponatraemia.
Community reports
Used for the "fullness" effect in physique contexts, which is water retention being pursued deliberately in a drug whose principal danger is water retention.
Components carrying the argument: Plasma volume expansion
| Question | Position |
|---|---|
| The one rule | Fluid restriction is part of the dose |
| Sodium checks | Day 7, ~1 month, then periodic |
| Higher risk | Age 65+, thiazides, SSRIs, NSAIDs, carbamazepine |
| Haemostatic use | Works only where factor stores exist; tachyphylaxis on repeat |
| Nephrogenic diabetes insipidus | Does not work — wrong lesion |
| Sport | Named on the WADA list as a masking agent |
For central diabetes insipidus: desmopressin with dose and route individualised and sodium monitored, with a sick-day plan agreed in advance. For nocturnal enuresis in children: enuresis alarms have better long-term cure rates; desmopressin acts faster and is often used situationally. For nocturia in adults: exclude the common causes first — evening fluid and alcohol, diuretic timing, sleep apnoea, heart failure, poorly controlled diabetes and prostatic obstruction all cause it and all have their own treatments.
Physical-chemistry reference for laboratory handling of the lyophilised material. Reproduced so that stability and concentration mathematics can be studied — see the calculator for the arithmetic and the reconstitution guide for sterile technique.
None for the oral, sublingual and nasal formulations. The injectable is a ready-to-use solution. There is no lyophilised research-grade presentation in normal circulation and this site publishes no reconstitution arithmetic for desmopressin.
Formulation-specific. Injectable and some nasal products are refrigerated; tablets and sublingual lyophilisate are stored at room temperature and protected from moisture. The sublingual lyophilisate is fragile and should be removed from the blister only immediately before use.
Injectable: 4 mcg/mL ampoules and vials. Tablets, sublingual lyophilisate and metered nasal sprays at strengths that differ substantially between indications.
The practical hazard is not degradation but confusion: strengths differ by more than tenfold between routes, and micrograms and milligrams appear on different products in the same family.
Regulatory status changes and differs by country. This is a summary for orientation, not legal advice — check your own jurisdiction.
Approved prescription medicine. Licensed for central diabetes insipidus, primary nocturnal enuresis, nocturia due to nocturnal polyuria, and haemostatic use in mild haemophilia A and von Willebrand disease type 1, with formulation-specific indications.
The nocturia formulations carry a boxed warning for hyponatraemia. Severe hyponatraemia can cause seizures, coma, respiratory arrest and death. Contraindicated in people at increased risk, including those on loop diuretics or systemic or inhaled glucocorticoids.
Prohibited in sport. Desmopressin is explicitly named on the WADA Prohibited List as a masking agent, at all times and in all sports.
Regulatory and trial claims re-checked against primary sources on 16 August 2026. Checked: hyponatraemia boxed warning and monitoring schedule. Approvals, trial readouts and compounding decisions move faster than anything else on this page — a date here means someone looked, not that nothing has changed since.
Explicitly prohibited. Desmopressin is named on the WADA Prohibited List under masking agents, prohibited at all times. This is not a borderline classification.
Links resolve to PubMed records, trial registries, publisher pages or primary documents. Where a body of work rather than a single paper is cited, the link opens a PubMed query so the full result set — including newer papers than this page — can be reviewed. Verify every claim against the primary source before relying on it.
For educational and research reference only. Nothing on this site is medical advice, a recommendation, or an instruction to administer any substance to a human being. Every figure on this page is a record of what has been reported, not a recommendation. Full disclaimer.
